E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.33
    -0.27 (-1.99%)

    Market Cap: $396.11M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(26/40)
    Avg Surprise
    +22.30%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.53
    Range$-0.66 - $-0.40
    3 analysts
    Revenue Consensus
    $14M
    Range$11M - $15M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.48
    Range$-0.48 - $-0.48
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.42+12.5%
    60d ago$-0.42+12.5%
    30d ago$-0.42+12.5%
    7d ago$-0.42+12.5%
    Current$-0.48
    Revenue Consensus
    $14M
    Range$14M - $14M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.48---
    Sep 26EST
    		-$-0.53---
    Jun 26
    		$-0.67$-0.37-81.08%Miss+21.2%
    Mar 26
    		$-0.45$-0.57+21.05%Beat+57.5%
    Dec 25
    		$-0.42N/A+52.27%Beat+60.0%
    Sep 25
    		$-0.87$-1.01+13.86%Beat+36.0%
    Jun 25
    		$-0.85$-0.88+3.41%Beat+20.6%
    Mar 25
    		$-1.06$-1.14+7.02%Beat+27.9%
    Dec 24
    		$-1.05$-1.35+22.22%Beat+33.5%
    Sep 24
    		$-1.36$-0.92-47.83%Miss-2.3%
    Jun 24
    		$-1.07$-1.41+24.11%Beat+42.5%
    Mar 24
    		$-1.47$-1.40-5.00%Miss+17.9%
    Dec 23
    		$-1.58$-1.23-28.46%Miss-13.7%
    Sep 23
    		$-1.33$-2.21+39.82%Beat-4.7%
    Jun 23
    		$-1.86$-2.19+15.07%Beat-21.6%
    Mar 23
    		$-1.79$-1.93+7.25%Beat-9.8%
    Dec 22
    		$-1.39$-1.60+13.13%Beat+6.1%
    Sep 22
    		$-1.27$-1.35+5.93%Beat-4.1%
    Jun 22
    		$-1.53$-1.39-10.07%Miss-28.6%
    Mar 22
    		$-1.63$-1.41-15.60%Miss-49.5%
    Dec 21
    		$-1.48$-1.11-33.33%Miss-261.0%
    Sep 21
    		$-1.22$-1.19-2.52%Miss+16.4%
    Jun 21
    		$-1.19$-1.29+7.75%Beat-67.6%
    Mar 21
    		$-1.09$-0.97-12.37%Miss-263.3%
    Dec 20
    		$-0.41$-0.77+46.75%Beat-163.1%
    Sep 20
    		$-1.46$-0.97-50.52%Miss-431.8%
    Jun 20
    		$-0.71$-0.96+26.04%Beat-315.2%
    Mar 20
    		$-0.30N/A+58.33%Beat-250.0%
    Dec 19
    		$0.65$0.60+8.33%Beat-48.0%
    Sep 19
    		$0.44$0.56-21.43%Miss-66.2%
    Jun 19
    		$0.33$0.17+94.12%Beat-66.0%
    Mar 19
    		$0.20$-0.05+500.00%Beat-67.2%
    Dec 18
    		$1.25$1.29-3.10%Miss+212.5%
    Sep 18
    		$1.30$1.19+9.24%Beat-30.1%
    Jun 18
    		$0.97$0.90+7.78%Beat+320.5%
    Mar 18
    		$0.61$0.25+144.00%Beat+317.9%
    Dec 17
    		$0.40$0.27+48.15%Beat+253.8%
    Sep 17
    		$1.86$2.13-12.68%Miss+2166.7%
    Jun 17
    		$-0.44$-0.48+8.33%Beat-
    Mar 17
    		$-0.28$-0.38+26.32%Beat-
    Dec 16
    		$-0.26$-0.18-44.44%Miss-
    Sep 16
    		$-0.09$-0.18+50.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-5.53EV/EBITDA41.13x
    Price/FCF-10.50xFCF Yield-9.53%
    Profitability
    Profit Margin-96.90%Operating Margin-120.00%
    ROE-70.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-4.38x
    Current Ratio3.76xQuick Ratio3.76x
    Trading Statistics
    Beta0.93Avg Volume224.16K
    52-Week High$17.1552-Week Low$7.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$13.65
    SMA 20$13.52
    SMA 50$13.56
    SMA 200$13.57
    EMA 10$13.62
    EMA 20$13.52
    EMA 50$13.42
    EMA 200$12.79

    MACD

    Line: 0.11Signal: 0.10Hist: 0.01

    ADX

    ADX: 12.7+DI: 22.4-DI: 23.2

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down12.0
    PSAR$12.99

    Bollinger Bands

    Upper Band$14.21
    Lower Band$12.82
    %B Position1028%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    47.9

    Momentum Oscillators

    Stoch %K40.1
    Stoch %D49.7
    Williams %R-69.9
    ROC (10d)3.9%
    Momentum0.50
    CCI (20d)-39.1
    MFI (14d)53.8

    Volatility Measures

    ATR (14d)$0.64(4.8%)
    StdDev (20d)0.35
    Hist Vol36.3%(Moderate)

    Volume Flow

    VWAP$13.35
    OBV16.3M
    AD Line12.5M
    CMF (20d)-0.035

    Volume Metrics

    Avg Vol (20d)227.0K
    Vol Ratio1.3x
    VWMA (20d)$13.54

    Pivot Points

    R3$14.29
    R2$14.10
    R1$13.85
    Pivot Point$13.66
    S1$13.41
    S2$13.22
    S3$12.97

    Advanced Oscillators

    TSI5.86
    Ultimate Osc49.5
    KST16.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$14.36M$17.16M$18.61M$15.13M$18.31M$14.93M$16.96M$14.61M$17.97M$17.05M$18.00M$18.93M
    Cost of Revenue$0$0$0$1.28M$0$0$0$479,000$0$0$0$669,000
    Gross Profit$14.36M$17.16M$18.61M$15.13M$18.31M$14.93M$16.96M$14.61M$17.97M$17.05M$18.00M$18.93M
    Operating Expenses$31.59M$29.01M$29.87M$33.51M$37.21M$39.45M$40.50M$44.46M$42.16M$49.82M$52.89M$49.96M
    R&D$22.13M$19.44M$20.86M$23.81M$27.21M$28.07M$27.66M$30.78M$28.74M$35.59M$36.37M$36.17M
    SG&A$9.47M$9.57M$9.01M$9.70M$10.00M$11.39M$12.85M$13.68M$13.41M$14.23M$16.52M$13.79M
    Operating Income$-17,236,000$-11,852,000$-11,253,000$-18,386,000$-18,893,000$-24,527,000$-23,543,000$-29,854,000$-24,185,000$-32,766,000$-34,886,000$-31,030,000
    Interest Income$1.90M$2.08M$2.42M$2.07M$2.29M$2.29M$2.80M$3.18M$3.49M$3.81M$4.30M$4.66M
    Interest Expense$4.13M$3.32M$3.08M$2.39M$1.62M$1.71M$1.96M$2.58M$2.35M$2.56M$3.44M$3.15M
    Income Before Tax$-19,465,000$-13,084,000$-11,914,000$-18,668,000$-18,226,000$-23,949,000$-22,706,000$-29,186,000$-23,053,000$-31,520,000$-34,029,000$-29,517,000
    Income Tax Expense$36,000$7,000$24,000$32,000$29,000$-1,305,000$-416,000$-363,000$-395,000$-363,000$-622,000$-1,410,000
    Net Income$-19,501,000$-13,091,000$-11,938,000$-18,700,000$-18,255,000$-22,644,000$-22,290,000$-28,823,000$-22,658,000$-31,157,000$-33,407,000$-28,107,000
    EBITDA$-16,043,000$-10,341,000$-10,003,000$-14,997,000$-17,670,000$-22,508,000$-22,022,000$-30,577,000$-23,826,000$-32,120,000$-22,022,000$-30,425,000
    EBIT$-17,236,000$-11,852,000$-11,253,000$-16,281,000$-18,893,000$-24,527,000$-23,543,000$-29,854,000$-24,185,000$-32,766,000$-23,543,000$-31,030,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENTA

    News

    Deep Track Capital, LP Trims Enanta Pharmaceuticals Inc (ENTA) S

    Deep Track Capital, LP significantly reduced its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by selling over 512,000 shares, decreasing its position by 26.20%. This move reflects a reassessment of Enanta, which is currently deemed "Significantly Overvalued" with a GF Value of $7.98 against a trading price of $13.14. The biotechnology company faces financial challenges, weak profitability, and growth metrics, prompting caution from institutional investors despite some recent price momentum.

    GuruFocus•8/21/26•
    Bearish

    Enanta Pharmaceuticals (Nasdaq:ENTA) - Stock Analysis

    This Simply Wall St analysis provides a detailed overview of Enanta Pharmaceuticals (ENTA), a biotechnology company specializing in small molecule drugs. The report covers the company's valuation, future growth prospects (revenue forecast to grow 21.99% annually), past performance, financial health, and dividend policy, noting it is currently unprofitable but analysts expect stock price growth. It also includes market data such as share price history, volatility, and comparison against industry and market returns.

    Simply Wall Street•8/12/26•
    Neutral

    Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses

    Enanta Pharmaceuticals (ENTA) experienced a 2.1% stock slip after reporting a Q3 loss with basic earnings per share at -$0.67 and a wider net loss of $19.50 million. While loss per share improved year-over-year, revenue declined from $18.31 million to $14.36 million, raising concerns about commercial cash flow and the company's ability to support its R&D pipeline amid continued losses and shareholder dilution. Investors are advised to consider the financing and execution risks associated with the company's early to mid-stage portfolio.

    Sahm•8/12/26•
    Bearish

    Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

    Enanta Pharmaceuticals Inc. reported a fiscal third-quarter loss of $19.5 million, or 67 cents per share. The biotechnology company generated $14.4 million in revenue during the period. This financial snapshot was generated by Automated Insights using data from Zacks Investment Research.

    Barchart.com•8/11/26•
    Bearish

    Enanta Pharma misses Q3 estimates on lower royalty revenue

    Enanta Pharmaceuticals missed its Q3 earnings and revenue estimates, reporting an adjusted EPS of -$0.67 against an expected -$0.50, and revenue of $14.4 million, short of the $17.4 million forecast. The shortfall was primarily due to lower royalty revenue from AbbVie’s hepatitis C virus regimen MAVYRET/MAVIRET. Despite the financial miss, Enanta highlighted progress in its RSV and immunology programs, with a Phase 2b pediatric trial underway for zelicapavir and a registrational trial expected to start in Q4 2026.

    Investing.com•8/11/26•
    Bearish

    Frequently Asked Questions About ENTA

    Does ENTA pay dividends?
    Enanta Pharmaceuticals Inc (ENTA) does not currently pay a regular dividend.
    What is ENTA's market cap?
    Enanta Pharmaceuticals Inc (ENTA) has a market capitalization of $396.11M with a current stock price of $13.33.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In